Quantum biopharma signs agreement to manufacture oral drug formulation of its potential breakthrough drug lucid-21-302 (lucid-ms) for use in its upcoming phase 2 multiple sclerosis trial

Toronto, aug. 11, 2025 (globe newswire) -- quantum biopharma ltd. (nasdaq: qntm) (cse: qntm) (fra: 0k91) (upstream: qntm) (“quantum biopharma” or the “company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, huge biopharma australia pty ltd., that it has signed an agreement with a leading contract development and manufacturing organization (cdmo) to manufacture an oral drug formulation of lucid-ms. the oral formulation of lucid-ms will serve as the drug product for the company's phase 2 clinical trial, which will test the efficacy on humans of lucid-ms as a possible treatment for people to gain back mobility lost with multiple sclerosis (ms). to date numerous animal models over the past decade showed lucid-ms helped those animals regain their ability to walk. videos can be seen at  https://www.quantumbiopharma.com/lucid-ms .
QNTM Ratings Summary
QNTM Quant Ranking